TCS 21311

• Description:

  TCS 21311 (NIBR3049) is a potent, highly selective JAK3 inhibitor with an IC50 of 8 nM, it displays >100-fold selectivity over JAK1, JAK2 and TYK2. TCS 21311 (NIBR3049) inhibits PKCα, PKCθ, and GSK3β with IC50s of 13, 68, and 3 nM, respectively[1].

• Product Name Alternative:

  NIBR3049

• UNSPSC:

  12352005

• Target:

  GSK-3; JAK; PKC

• Type:

  Reference compound

• Related Pathways:

  Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; TGF-beta/Smad

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/tcs-21311.html

• Purity:

  99.49

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C(C1=CC(N2CCN(C(C(C)(O)C)=O)CC2)=CC=C1C(F)(F)F)=C3C4=CNC5=C4C=CC=C5)NC3=O

• Molecular Formula:

  C27H25F3N4O4

• Molecular Weight:

  526.51

• References & Citations:

  [1]Thoma G, et al. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.J Med Chem. 2011 Jan 13;54 (1) :284-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  GSK-3β; JAK1; JAK2; JAK3; PKCα; PKCθ

• CAS Number:

  [1260181-14-3]